Home Featured

Featured

Random

MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company

PT313 – Christine Calvert, LCDC – Holotropic Breathwork, Ethics, and Dying To Ourselves

Red Light Holland Receives Receipt for Final Short-form Prospectus for Previously Announced $10 Million Bought Deal Public Offering

Psychedelic Research Bulletin: November 2022

PTSF49 – MDMA For Alcoholism, The Placebo Effect, and Ceremonial Magicians

Psychedelic Therapy for Borderline Personality Disorder?

PsyBio Therapeutics Corp. Begins Trading on the TSX Venture Exchange

Can Psilocybin Assisted Psychotherapy Change Attachment Style?

It’s Time to Push Back: Meta’s War on Psychedelic Voices

atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical...

Psychedelic Bulletin #124: MAPS Wraps Second Phase 3 MDMA Trial; Preparing...

The Intertwined Prohibitionist Histories of Psychedelics and Kratom

Bright Minds Biosciences Strengthens Scientific Advisory Team to Prepare for Future...

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy...

12 3...296 Page 1 of 296

EDITOR PICKS

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.